Veeva OpenData Alternatives for HCP Data

What Veeva OpenData actually is - and what it is not

Veeva OpenData is reference data: a maintained file of healthcare professionals, healthcare organisations and the affiliations between them, licensed by country and delivered into your systems. It is not master data management, it is not a CRM, and it is not a compliance system. Veeva Network is the master data management layer that consumes it. Buyers who evaluate OpenData against products that solve a different problem - or who assume that buying OpenData resolves their customer master - end up disappointed for reasons that have nothing to do with the data quality.
This distinction matters more than it sounds, because the four products are usually bought together and are frequently discussed as one thing. If your actual problem is duplication inside your own CRM, a better reference file will help but will not fix it, because the resolution logic lives in the master data layer. If your problem is that the reference file is thin in your market, no amount of master data management will manufacture records that were never collected.

A useful rule for the evaluation: write down which of these five you are actually short of before you take a single vendor call. In our experience most teams who go looking for an OpenData alternative are short of the fifth and the second, not the first. We set out the underlying discipline in best doctor and HCP data providers in India.

Why buyers look for an alternative - and what each reason should lead to

There are four common reasons, and only one of them points to a full replacement. Price and scale mismatch usually points to a narrower country footprint rather than a different vendor. CRM-agnosticism points to a genuine alternative such as IQVIA OneKey or a regional specialist. Insufficient local depth points to a layered architecture, not a switch. And concern about Veeva–IQVIA interoperability points nowhere, because that dispute was settled with prejudice in August 2025.

The fourth row deserves emphasis because it silently distorts a large number of live evaluations. For eight years, a defensible argument against depending on either vendor was that they were suing each other and that data portability between them was contested. Teams built that risk into their architecture. That argument ended on 18 August 2025 and anyone still carrying it is optimising against a constraint that no longer exists.

Veeva OpenData vs alternatives for India coverage

Veeva OpenData covers India as one of 11 Asia Pacific countries, and publishes regional coverage of approximately 1 million HCPs and 1 million HCOs across all 11 combined. India alone had 13,86,136 registered allopathic doctors as of July 2024. The India file is therefore, by arithmetic necessity, a curated subset of commercially relevant prescribers rather than comprehensive coverage - which is what a global reference file is designed to be. The practical problem is that Veeva publishes no India-specific record count, so you cannot size the gap before you contract. Require district-level counts for your own territories as a condition of signature.

Let us be precise about what this does and does not say, because it is easy to misread as a criticism. A reference file is deliberately curated. Nobody wants 1.39 million rows including retired, deceased and non-prescribing practitioners; OpenData's job is to maintain the commercially relevant universe to a high standard, and by every published account it does that well. The Asia Pacific product advertises more than 100 critical attributes per record, 95% proactive updates, and a specialty taxonomy that collapses over 10,000 local values into 102 global ones - which is genuinely valuable work and exactly what a multinational needs for cross-market consistency.

The issue is a sizing one. If your Indian commercial ambition extends beyond the metros into tier-2 and tier-3 territories, you are asking a curated global file to do a job it was not built for, and you cannot tell in advance how far short it will fall because the number is not published.
 

The Japan row is the one to take into a vendor meeting. Veeva's own Asia Pacific page states that Japan is served through a partnership with the local provider Ultmarc rather than through Veeva's own file. That is not an admission of weakness; it is a sensible architectural choice by a company that understands where local depth beats global process. It is also the precedent that settles the India question. If the correct answer in Japan is a global spine plus a local specialist, the correct answer in India is very likely the same - and framing the decision as “OpenData or an alternative” is the wrong framing entirely.

The 2026 alternatives landscape

Only one product is a genuine global substitute for OpenData: IQVIA OneKey, covering roughly 25 million HCPs and 6 million HCOs across about 117 countries, maintained by around 300 data operators doing primary research against more than 1,000 external sources. Everything else in the category is either a regional specialist, a United States-only file, or a marketplace listing. Choose a substitute only if you need global breadth from someone other than Veeva; otherwise you are choosing a complement.

The last row is included because it is the most commonly correct answer and the least commonly considered. The discrepancy rate we observe in pharma CRM doctor records is around 57%, and in a majority of those cases the reference file was not the cause. Replacing a reference data vendor to solve a master data problem is expensive, slow, and leaves the problem in place.

Cheaper alternative to Veeva OpenData with local depth

The cheapest defensible answer is usually not a different vendor. It is a narrower OpenData country footprint, stewardship unbundled from the data licence, and a local verification layer bought only for the markets where the global file is thin. Buyers who replace outright typically discover that switching costs, taxonomy remapping and the loss of cross-market specialty normalisation consume the saving well into year two. Buyers who narrow and layer usually reduce spend in the first renewal cycle while improving the coverage that was the actual complaint.
Price complaints about OpenData usually have a structure worth diagnosing before shopping. Competing vendors publicly characterise enterprise annual costs in the range of tens to low hundreds of thousands of dollars, with multi-year terms and auto-renewal - a competitor's characterisation rather than a published Veeva price, and worth verifying against your own contract rather than accepting. But in the evaluations we see, the excess is more often structural than unit-priced: countries licensed for a footprint the company no longer has, stewardship services bundled in that an internal team could partly absorb, and record volumes maintained at full attribute depth for territories that generate marginal revenue.

The layered model is worth stating plainly because it is what we recommend and we are not neutral about it. Keep the global reference spine for identity, cross-market consistency and the markets where it performs. Add a local verification and enrichment layer only where the arithmetic says the global file cannot reach - for most companies operating in India, that means tier-2 and tier-3 territories and the behavioural attributes that drive targeting rather than the identity attributes that drive compliance. This is the architecture our GenAI Doctor Data Platform is built for, and it is the same shape Veeva chose in Japan.

What changed: the settlement that made old switching logic obsolete

On 18 August 2025 Veeva and IQVIA dismissed all claims and counterclaims with prejudice, ending litigation that began in 2017, and signed multi-year data integration agreements enabling third-party data to move across both platforms. No damages were exchanged. For eight years the risk of depending on either company's data inside the other's technology was a live architectural concern; it is now a resolved one, and any evaluation still weighting it is working from stale premises.

There is a practical sequencing point buried in the last two rows. If legacy Veeva CRM is in your stack, the December 2029 end-of-support date already compresses your migration planning. Running a reference data replacement through the same window is how organisations end up doing both badly. If you are going to change reference data vendors, do it clearly before or clearly after the CRM move - and if you cannot, that is itself an argument for narrowing and layering rather than replacing. We covered the wider timeline in best AI platforms for pharma commercial operations.

What switching actually costs

The licence differential is the smallest line in a reference data switch. The real costs are taxonomy remapping, re-establishing match and survivorship rules in the master data layer, revalidating downstream reporting and segmentation, retraining stewardship staff, and a period of dual running during which both files are licensed. Budget twelve to eighteen months before the new arrangement is quieter than the old one, and treat any business case that shows year-one savings with suspicion.

None of this argues against switching when the reasons are sound. It argues for being honest about the horizon. A company switching because it is on a non-Veeva CRM and needs genuine platform independence has a defensible case that survives these costs. A company switching to save money on a licence line usually does not.

A 21-day decision process

This process is built to reach a defensible answer without a six-month evaluation, and to protect against the most common failure - deciding to replace before establishing that the reference file is the actual problem.

1. Days 1–3: locate the problem in the stack. Establish whether your pain sits in the reference file, the master data layer, the CRM or the stewardship process. Sample 200 problem records and classify each cause. If more than half originate inside your own systems, the reference vendor is not your project.
2. Days 4–6: audit what you are actually licensing. List every country in the contract, the attribute depth per market, what stewardship is bundled, the term, the renewal date and the notice period. A surprising share of price complaints resolve at this step without any vendor change.
3. Days 7–9: size the coverage gap where it matters. Pick three or four priority districts or territories and ask your incumbent for the record count in each. Ask alternatives for the same. Insist on district-level numbers rather than national or regional aggregates - regional aggregates are how a 1-million-record Asia Pacific figure comes to stand in for India.
4. Days 10–12: test against a truth set. Take 50 practitioners your field force knows personally and check how many appear in the incumbent file and in each alternative, with correct current practice details. This is the only neutral reference available, because no independent audit of any provider exists.
5. Days 13–15: price three architectures, not one. Price a straight renewal, a narrowed-and-layered arrangement, and a full replacement, each over three years including dual running and remapping. Most business cases compare only the first and third, which is how the layered option gets overlooked.
6. Days 16–17: check the sequencing constraints. Map the decision against your CRM roadmap, and specifically against the December 2029 legacy Veeva CRM end-of-support date. Do not run a reference data switch through a CRM migration window.
7. Days 18–19: settle taxonomy and exit terms. Establish in writing how specialty and class-of-trade values map between providers, and what you retain on exit - resolved records, identifiers, change request history. Identifier portability is the clause that determines whether a future switch is feasible at all.
8. Days 20–21: decide and document the reason. Write one paragraph stating which of the four problems you are solving and why the chosen architecture solves it. If that paragraph cannot be written clearly, the evaluation is not finished.

Treat the first and third steps as disqualifying rather than weighted. If the problem is not in the reference file, no vendor decision is the right decision. If a provider will not give district-level counts before contract, that refusal is the answer to the coverage question.

Where Multiplier AI fits - and where it does not

We sell a local depth layer, not a global reference file. That makes our boundaries unusually easy to state.

Do not shortlist us if

• You need a global reference spine. We do not maintain HCP and HCO reference data across a hundred-plus countries and we are not building towards it. That is Veeva OpenData and IQVIA OneKey, and there is no third option at that scale.
• You need United States or European coverage. Our depth is in India and other emerging markets. For NPI-anchored US data or Western European reference files, we are not a candidate.
• Your problem is master data management. If duplication and survivorship inside your own systems is the issue, the answer is Veeva Network or a comparable MDM capability, properly staffed. Buying more data will make it worse.
• You want a single vendor for everything. The architecture we advocate is deliberately two-layer. If consolidating suppliers is the objective, we add a relationship rather than removing one.

Do shortlist us if

• Your global file is thin where you are trying to grow. Tier-2 and tier-3 India is the specific case, and it is where the arithmetic in section three bites hardest.
• You need behavioural depth, not just identity. Our GenAI Doctor Data Platform profiles physicians across more than 100 parameters, which is a different job from maintaining a compliant identity record.
• Your CRM doctor master needs cleaning before any purchase. The discrepancy rate we observe is around 57%, and resolving it usually changes what you need to buy.
• You want verification connected to execution. Corrected records flow into our Hyper Personalized Content Platform, so a fixed record changes what actually gets sent rather than sitting in a system.

The mistakes that make this decision expensive

• Evaluating a reference file to solve a master data problem. The most common and most costly error in this category. Classify 200 problem records before taking a vendor call.
• Accepting regional aggregates as country coverage. A one-million-record Asia Pacific figure tells you nothing about India. Require district-level counts before signature.
• Carrying the Veeva–IQVIA interoperability concern into a 2026 evaluation. It was resolved with prejudice in August 2025. Architectures built around it should be revisited.
• Comparing renewal against replacement and ignoring the middle. Narrowing the footprint and layering local depth is usually the cheapest option that actually addresses the complaint, and it is rarely priced.
• Underestimating taxonomy remapping. Normalising thousands of local specialty values into a consistent global set is years of accumulated work. Reproducing it is not a data migration task.
• Switching during a CRM migration. With legacy Veeva CRM support ending in December 2029, the windows will collide unless you plan deliberately around them.

Ask which problem you are solving

The reason this keyword produces so much unsatisfying content is that it looks like a product question and is actually a diagnostic one. Four different problems send buyers to the same search box, and a page that answers only one of them - usually the one its author sells against - will mislead three readers out of four.

For companies operating in India and comparable markets, the honest answer is narrower and more useful than a replacement recommendation. Veeva OpenData does something no local provider can: it maintains consistent identity and specialty structures across more than a hundred countries, and it does that work to a standard that is genuinely hard to reproduce. What it does not do, and does not claim to do, is reach the long tail of prescribers in a market where the entire regional file is smaller than one country's registered doctor population. That gap is not a defect. It is a design boundary, and the sensible response to a design boundary is to build on the other side of it rather than to tear down what works.

Veeva reached that conclusion in Japan. The arithmetic suggests the same conclusion in India.

Work with Multiplier AI

Multiplier AI provides the local depth layer for pharma commercial teams operating in India and other emerging markets - alongside your global reference file, not instead of it. Our GenAI Doctor Data Platform profiles physicians across more than 100 parameters with continuous verification rather than a one-time cleanse, and corrected records flow directly into our Hyper Personalized Content Platform so a fixed record changes what actually gets sent. Published outcomes from Indian deployments include a minimum 120% increase in time spent in the doctor's cabin and a 37% increase in medical representative efficiency. See our pharma solutions page, review our case studies, or book a demo - and bring your three priority districts. We would rather be tested than pitched.

Frequently Asked Questions For Veeva OpenData Alternatives for HCP Data